Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.68 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.68 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAOB | P27338 | 1/20 | 0.55 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.54 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.54 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.54 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.54 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.53 |
| ▸ | PRKCA | P17252 | 1/20 | 0.53 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.53 |
| ▸ | MMP8 | P22894 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27900716 | 0.94 | LMNA (0.65) | LMNAL3MBTL1NR1H4ALDH1A1MAOB | |
| SCHEMBL6311563 | 0.93 | LMNA (0.64) | LMNAL3MBTL1NR1H4ALDH1A1MAOB | |
| SCHEMBL31579489 | 0.90 | LTA4H (0.60) | LMNAL3MBTL1ALDH1A1MAOBALOX5 | |
| SCHEMBL7401422 | 0.87 | LMNA (0.71) | LMNAL3MBTL1NR1H4ALDH1A1MAOB | |
| SCHEMBL27973452 | 0.86 | LMNA (0.65) | LMNAL3MBTL1NR1H4ALDH1A1MAOB | |
| SCHEMBL27759836 | 0.85 | LMNA (0.55) | LMNAL3MBTL1NR1H4ALDH1A1 | |
| SCHEMBL27759813 | 0.85 | LMNA (0.55) | LMNAL3MBTL1NR1H4ALDH1A1 | |
| SCHEMBL8871420 | 0.85 | LMNA (0.64) | LMNAL3MBTL1NR1H4ALDH1A1MAOB | |
| SCHEMBL11252632 | 0.84 | LTA4H (0.56) | LMNAL3MBTL1MAOBALOX5NR4A1 | |
| SCHEMBL14504374 | 0.83 | LMNA (0.62) | LMNAL3MBTL1NR1H4ALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8772302-B2 | GPR 119 agonists | CADILA HEALTHCARE LIMITED (IN) | 2014-07-08 | — | — | US | disclosed |
| EP-2445904-B1 | 1,3,2-DIOXATHIANE-2-OXIDE DERIVATIVES AND THEIR USE AS GPR 119 AGONISTS | CADILA HEALTHCARE LTD (IN) | 2013-09-11 | — | — | EP | disclosed |
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2012-05-17 | — | — | US | disclosed |
| EP-2445904-A1 | NOVEL GPR 119 AGONISTS | Cadila Healthcare Limited (IN) | 2012-05-02 | — | — | EP | disclosed |
| WO-2010146605-A1 | NOVEL GPR 119 AGONISTS | CADILA HEALTHCARE LIMITED (IN) | 2010-12-23 | — | — | WO | disclosed |
| US-6326369-B1 | ALZHEIMER'S DISEASE | TAKEDA CHEMICALS INDUSTRIES, LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
| EP-0968164-A1 | BICYCLIC QUINONE COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 2000-01-05 | — | — | EP | disclosed |
| WO-1998033758-A1 | BICYCLIC QUINONE COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1998-08-06 | — | — | WO | disclosed |
| EP-0510526-B1 | Use of sulfonamides as drug and new sulfonamides | HOFFMANN LA ROCHE (CH) | 1996-12-04 | — | — | EP | disclosed |
| EP-0510526-A1 | Use of sulfonamides as drug and new sulfonamides | F.HOFFMANN-LA ROCHE & CO. AKTIENGESELLSCHAFT (CH) | 1992-10-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122905-A1 | NOVEL GPR 119 AGONISTS | GPR119, GPR4, GPR39 | LMNA 4491/4885L3MBTL1 4650/4885NR1H4 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.